Tvardi Therapeutics, Inc.
TVRDNASDAQ
Healthcare
$3.03
+0.03(1.00%)
Mkt Cap $28M
$3.00
$42.98
52-Week Range
At a Glance
AI-generatedTvardi Therapeutics reported narrower losses in FY2025 compared to the prior year, driven by reduced clinical trial activity and cost adjustments following the discontinuation of certain programs, though the company continues to operate without revenue and remains dependent on external financing.
8-K
Tvardi Therapeutics reported a reduced net loss of $7.3 million for Q4 2025 and announced upcoming clinical milestones for its STAT3 inhibitors TTI-101 and TTI-109, with cash expected to fund operations into Q4 2026.$28M
Market Cap
$4M
Revenue
-$14M
Net Income
Employees17
Fundamentals
How The Business Makes Money
Tvardi Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases with significant unmet need. Their lead candidate, TTI-101, is currently in Phase 2 clinical trials for idiopathic pulmonary fibrosis (IPF) and hepatocellular carcinoma (HCC).
Industry Biotechnology
Activity
What Changed Recently
Analyst View
Company Profile
CIK0001346830
ISINUS1407553072
CUSIP140755307
Phone832-413-1362
Address2450 Holcombe Blvd, Suite X, Sugar Land, TX, 77021, US
SEC EDGAR